Calidi Biotherapeutics, Inc. (CLDI) Stock

Calidi Biotherapeutics, Inc. (CLDI) is a Healthcare stock trading at $1.32 (as of 2026-08-21), with a market capitalization of $3.41M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing cell-based immunotherapies for cancer. Its pipeline includes NeuroNova (allogeneic neural stem cells carrying an oncolytic adenovirus) for high-grade gliomas and SuperNova (allogeneic adipose-derived mesenchymal stem cells carrying a tumor-selective oncolytic vaccinia virus) for advanced metastatic solid tumors.

Valuation — source: SEC EDGAR (first-party)
Price$1.32
Market Cap$3.41M
Price / Book1.09
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$45000.00
Net Margin7844.9%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFinepoint Capital LP ($249000.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOEric E. Poma
Employees28
CountryUS
IPO Date2021-11-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Jasper Therapeutics, Inc. (JSPR)
  • Intensity Therapeutics, Inc. (INTS)
  • Passage Bio, Inc. (PASG)
  • IN8bio, Inc. (INAB)
  • Senti Biosciences, Inc. (SNTI)
  • Creative Medical Technology Holdings, Inc. (CELZ)
  • VivoSim Labs, Inc. (VIVS)
  • AIM ImmunoTech Inc. (AIM)
CLDI earnings history · CLDI institutional & insider holders · CLDI KPIs & operating metrics · CLDI financials · CLDI investor presentations & press releases · CLDI SEC filings · CLDI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.